Randomized controlled trials (RCTs) have traditionally been the gold standard for determining whether a treatment is empirically supported. Nevertheless, there has been an increase in criticism of RCTs for psychotherapeutic research due to their high rate of biases, lack of replicability, and discrepancies in real-world applications. The author discusses the weaknesses of RCTs and the need to refine how we view psychotherapeutic treatments as efficacious.